Metformin in patients with ischemic heart disease and type 2 diabetes mellitus: mechanism of action and clinical efficiency

Diabetes mellitus is one of the leading causes of death in modern society, primarily due to its cardiovascular complications. This factor drives search for novel pharmacologic agents to affect not only glycemic levels, but also the cardiovascular prognosis in diabetic patients with ischemic heart di...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Ekaterina Nikodimovna Kravchuk, M M Galagudza
Formato:	article
Lenguaje:	EN RU
Publicado:	Endocrinology Research Centre 2013
Materias:	diabetes mellitus type 2 metformin amp-activated protein kinase ischemic heart disease Nutritional diseases. Deficiency diseases RC620-627
Acceso en línea:	https://doaj.org/article/94aae411be3e471ab0f044046e06eeb0
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:94aae411be3e471ab0f044046e06eeb0
record_format	dspace
spelling	oai:doaj.org-article:94aae411be3e471ab0f044046e06eeb02021-11-14T09:00:17ZMetformin in patients with ischemic heart disease and type 2 diabetes mellitus: mechanism of action and clinical efficiency2072-03512072-037810.14341/2072-0351-3590https://doaj.org/article/94aae411be3e471ab0f044046e06eeb02013-03-01T00:00:00Zhttps://www.dia-endojournals.ru/jour/article/view/3590https://doaj.org/toc/2072-0351https://doaj.org/toc/2072-0378Diabetes mellitus is one of the leading causes of death in modern society, primarily due to its cardiovascular complications. This factor drives search for novel pharmacologic agents to affect not only glycemic levels, but also the cardiovascular prognosis in diabetic patients with ischemic heart disease. Recent studies demonstrate that aside from basic blood glucose lowering action, metformin shows beneficial influence on blood rheology and vascular tone, hemostasis, oxidative stress, lipid spectrum and delivers and an ant-ischemic effect. Here we review clinical and experimental evidence on cardio- and vasoprotective effects of metformin, highlighting their molecular mechanisms.Ekaterina Nikodimovna KravchukM M GalagudzaEndocrinology Research Centrearticlediabetes mellitus type 2metforminamp-activated protein kinaseischemic heart diseaseNutritional diseases. Deficiency diseasesRC620-627ENRUСахарный диабет, Vol 16, Iss 1, Pp 5-14 (2013)
institution	DOAJ
collection	DOAJ
language	EN RU
topic	diabetes mellitus type 2 metformin amp-activated protein kinase ischemic heart disease Nutritional diseases. Deficiency diseases RC620-627
spellingShingle	diabetes mellitus type 2 metformin amp-activated protein kinase ischemic heart disease Nutritional diseases. Deficiency diseases RC620-627 Ekaterina Nikodimovna Kravchuk M M Galagudza Metformin in patients with ischemic heart disease and type 2 diabetes mellitus: mechanism of action and clinical efficiency
description	Diabetes mellitus is one of the leading causes of death in modern society, primarily due to its cardiovascular complications. This factor drives search for novel pharmacologic agents to affect not only glycemic levels, but also the cardiovascular prognosis in diabetic patients with ischemic heart disease. Recent studies demonstrate that aside from basic blood glucose lowering action, metformin shows beneficial influence on blood rheology and vascular tone, hemostasis, oxidative stress, lipid spectrum and delivers and an ant-ischemic effect. Here we review clinical and experimental evidence on cardio- and vasoprotective effects of metformin, highlighting their molecular mechanisms.
format	article
author	Ekaterina Nikodimovna Kravchuk M M Galagudza
author_facet	Ekaterina Nikodimovna Kravchuk M M Galagudza
author_sort	Ekaterina Nikodimovna Kravchuk
title	Metformin in patients with ischemic heart disease and type 2 diabetes mellitus: mechanism of action and clinical efficiency
title_short	Metformin in patients with ischemic heart disease and type 2 diabetes mellitus: mechanism of action and clinical efficiency
title_full	Metformin in patients with ischemic heart disease and type 2 diabetes mellitus: mechanism of action and clinical efficiency
title_fullStr	Metformin in patients with ischemic heart disease and type 2 diabetes mellitus: mechanism of action and clinical efficiency
title_full_unstemmed	Metformin in patients with ischemic heart disease and type 2 diabetes mellitus: mechanism of action and clinical efficiency
title_sort	metformin in patients with ischemic heart disease and type 2 diabetes mellitus: mechanism of action and clinical efficiency
publisher	Endocrinology Research Centre
publishDate	2013
url	https://doaj.org/article/94aae411be3e471ab0f044046e06eeb0
work_keys_str_mv	AT ekaterinanikodimovnakravchuk metformininpatientswithischemicheartdiseaseandtype2diabetesmellitusmechanismofactionandclinicalefficiency AT mmgalagudza metformininpatientswithischemicheartdiseaseandtype2diabetesmellitusmechanismofactionandclinicalefficiency
_version_	1718429595102871552

Metformin in patients with ischemic heart disease and type 2 diabetes mellitus: mechanism of action and clinical efficiency

Ejemplares similares